Related Experiment Video
Updated: Apr 18, 2026
11:44
A High Resolution Method to Monitor Phosphorylation-dependent Activation of IRF3
Published on: January 24, 2016
12.6K
Breaking up is hard to do: PI3K isoforms on the rebound
David W Cescon1, Chiara Gorrini2, Tak W Mak2
1Campbell Family Institute for Breast Cancer Research, Princess Margaret Cancer Centre/University Health Network, Toronto, ON M5T 2M9, Canada; Medical Oncology and Hematology, Princess Margaret Cancer Centre/University Health Network and University of Toronto, ON M5T 2M9, Canada.
Cancer Cell
|January 14, 2015
Summary
In cancer, inhibiting PI3Kα or PI3Kβ triggers the other isoform, causing PI3K activity to rebound via compensatory pathways. This highlights a critical mechanism in cancer cell survival.
Area of Science:
- Oncology
- Molecular Biology
- Biochemistry
Background:
- The phosphoinositide 3-kinase (PI3K) pathway is frequently dysregulated in cancer.
- PI3K signaling regulates cell growth, proliferation, and survival.
- Specific PI3K isoforms, such as PI3Kα and PI3Kβ, play distinct roles in cellular processes.
Purpose of the Study:
- To investigate compensatory mechanisms within the PI3K pathway upon isoform-specific inhibition.
- To understand how cancer cells maintain PI3K activity when key isoforms are targeted.
Main Methods:
- Utilized cancer cell models with hyperactivated PI3Kα or PI3Kβ.
- Performed isoform-specific inhibition of PI3Kα and PI3Kβ.
- Analyzed PI3K activity and downstream signaling.
Main Results:
- Inhibition of PI3Kα in cells with hyperactivated PI3Kα led to the activation of PI3Kβ.
- Conversely, PI3Kβ inhibition in cells with hyperactivated PI3Kβ resulted in PI3Kα activation.
- Observed a rebound in overall PI3K activity through distinct compensatory mechanisms.
Conclusions:
- Cancer cells employ isoform-specific compensation to maintain PI3K pathway activity.
- Targeting a single PI3K isoform may not be sufficient due to compensatory activation of other isoforms.
- Understanding these rebound mechanisms is crucial for developing effective PI3K-targeted cancer therapies.
More Related Videos
Related Concept Videos
01:22PI3K/mTOR/AKT Signaling Pathway
6.5K
The mammalian target of rapamycin (mTOR) is a serine/threonine kinase that regulates growth, proliferation, and cell survival in response to hormones, growth factors, or nutrient availability. This kinase exists in two structurally and functionally distinct forms: mTOR complex 1 (mTORC1) and mTOR complex 2 (mTORC2). The first form (mTORC1) is composed of a rapamycin-sensitive Raptor and proline-rich Akt substrate, PRAS40. In contrast, mTORC2 consists of a...
6.5K
01:42Phosphoinositides and PIPs
11.8K
Phosphoinositides are a group of phospholipids containing a glycerol backbone with two fatty acid chains and a phosphate attached to a myoinositol sugar ring. The inositol head group extends into the cytoplasm, where it is modified by adding phosphate groups to form phosphatidylinositol phosphates or PIPs.
Different phosphoinositides are synthesized and recruited on the cytosolic face of the plasma membrane. The localization of specific phosphoinositides concentrated in separate membrane...
Different phosphoinositides are synthesized and recruited on the cytosolic face of the plasma membrane. The localization of specific phosphoinositides concentrated in separate membrane...
11.8K
01:11IP3/DAG Signaling Pathway
16.2K
Membrane lipids such as phosphatidylinositol (PI) are precursors for several membrane-bound and soluble second messengers. Specific kinases phosphorylate PI and produce phosphorylated inositol phospholipids. One such inositol phospholipids are the phosphatidylinositol-4,5 bisphosphate [PI(4,5)P2], present in the inner half of the lipid bilayer. Upon ligand binding, GPCR stimulates Gq proteins to turn on phospholipase Cꞵ. Activated phospholipase Cꞵ cleaves PI(4,5)P2 and...
16.2K
01:20The JAK-STAT Signaling Pathway
14.2K
Several cytokine receptors have tightly bound Janus kinase or JAK proteins attached at their cytosolic tail. Small signaling molecules such as cytokines, growth hormones, or prolactins bind to the cytokine receptors and initiate their dimerization. The dimerization brings the cytosolic JAKs together that trans-phosphorylate and activates each other. The activated JAKs now phosphorylate cytosolic tails of the cytokine receptors, which serve as binding sites for adaptor proteins such as SH2...
14.2K
01:15Amplifying Signals via Second Messengers
9.6K
Many receptor binding ligands are hydrophilic; they do not cross the cell membrane but bind to cell-surface receptors. Thus, their message must be relayed by second messengers present in the cell cytoplasm. There are several second messenger pathways, each with its own way of relaying information. For example, the G protein-coupled receptors can activate both phosphoinositol and cyclic AMP (cAMP) second messenger pathways. The phosphoinositol pathway is active when the receptor induces...
9.6K
01:22Amplifying Signals via Enzymatic Cascade
19.7K
When a ligand binds to a cell-surface receptor, the receptor's intracellular domain changes shape, which may either activate its enzyme function or allow its binding to other molecules. The initial signal is amplified by most signal transduction pathways. This means that a single ligand molecule can activate multiple molecules of a downstream target. Proteins that relay a signal are most commonly phosphorylated at one or more sites, activating or inactivating the protein. Kinases catalyze...
19.7K